Valbiotis: Recruitment closed for the Cardio-Liver study

Valbiotis has announced the completion of recruitment for 70 participants in the Cardio-Liver clinical trial, which aims to evaluate the impact of TOTUM-448 on metabolic liver diseases. Conducted in partnership with Laval University, this four-month, randomized, double-blind study divides participants into two groups: one receiving TOTUM-448, the other a placebo. The study explores various metabolic parameters, with results expected in the second half of 2026.

TOTUM-448, whose efficacy is already recognized, will be marketed in France and Asia. Valbiotis aims to address the market for the prevention of metabolic liver diseases, affecting nearly 1 billion adults worldwide.